ClinicalTrials.gg
RecruitingNCT05856370Updated Aug 17, 2026

The Ailliance Post-Market Clinical Study

An interventional study of Follow-up schedule: pre-operative baseline up to 24-months post-procedure in Spinal Deformity, Spinal Degenerative Disorder and Spinal Fusion Failure, sponsored by Medtronic Spinal and Biologics. Recruiting at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Medtronic Spinal and Biologics (part of Medtronic) · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to collect performance and safety data for post-market Medtronic devices indicated for cranial and/or spinal indication(s).

Subjects are enrolled and followed postoperatively to 24 months. The Ailliance clinical study is intended to collect data congruous with routine clinical care practices.

02

Conditions studied

  • Spinal Deformity
  • Spinal Degenerative Disorder
  • Spinal Fusion Failure
  • Spinal Trauma
  • Spinal Tumor Case
03

In context

Lead sponsor

Medtronic Spinal and Biologics is the lead sponsor of 57 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject provides written per institution and/or geographical requirements.
  2. Subject is intended to receive or be treated with an eligible Medtronic Cranial and Spinal Technology (CST) device(s) (see product appendices), used alone or in combination, for a cranial and/or spinal indication(s).
  3. Subject is at least 18 years of age or minimum legal age as required by local regulations.
  4. Subject agrees to complete all required assessments per the Schedule of Events.

Exclusion criteria

Exclusion Criteria:

  1. Subject is currently enrolled or plans to enroll in concurrent drug/device/biologic trial(s) that may confound this trial's results per investigator assessment (i.e. no required intervention that could affect interpretation of all-around device safety and or performance).
  2. Subject who is, or is expected to be, inaccessible for all required follow-up visits.
  3. Subject with exclusion criteria required by local law.
  4. Subject is considered vulnerable at the time of obtaining consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    Receiving eligible Medtronic device(s) from all product groups

    Powered Systems, Instruments, and Imaging device(s), Advanced Energy device(s), Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)

    Device: Follow-up schedule: pre-operative baseline up to 24-months post-procedure

Interventions

  • DeviceFollow-up schedule: pre-operative baseline up to 24-months post-procedure

    Follow-up assessments will be required (therefore interventional) from pre-operative baseline to 24 months post index surgery

06

What researchers measure

Primary outcomes

  1. Surgical success (for any Medtronic eligible market-released Advanced Energy device(s) used)

    Defined by amount of: 1) blood loss (mL) during surgery and/or 2) total operation time and/or 3) length of stay in the hospital (measured from surgery completion to discharge), and/or 4) investigator opinion on whether the device(s) directly assisted in the completion of surgery

    Time frame: Discharge (from Index Surgery completion to 14 days post-operatively)

  2. Fusion Success (for any Medtronic eligible market-released Interbodies and Biologics, Other Spinal Hardware, and/or Rods and Screws device(s) used)

    Fusion success at 12-months is determined through evaluation of radiographic evidence (X-ray and/or CT scan) by the investigator by: (1) Confirming the presence of bone bridging, and (2) if using the Brantigan \& Steffee's Classification scale: a score D and/or E are determined.

    Time frame: 12 months

  3. Surgical performance (for any Medtronic eligible market-released Powered Systems, Instruments, and Imaging device(s) used)

    Surgical performance, as defined as the rate at which the device directly assisted in the completion of surgery in the investigator's opinion. If O-Arm used: whether O-Arm was utilized for validation of implant placement during the surgery.

    Time frame: Index Surgery

  4. Device performance (for any Medtronic eligible market-released Robotics and Navigation device(s) used)

    Robotics: Planned number of screws prior to index surgery compared to number of screws device assisted with placement during surgery. Navigation: Whether or not device was utilized for validation of screw placement during surgery.

    Time frame: 24 months

  5. Pain Resolution (for select Medtronic eligible market-released Other Spinal Hardware device(s) used)

    Resolution of pain at 12-months when compared to baseline Pain reported by the subject using the Neck Disability Index (NDI) questionnaire

    Time frame: 12 months

  6. Stabilization (for any Medtronic eligible market-released device(s) used from the following product groups: Other Spinal Hardware)

    * Stabilization is the radiographic verification of no noticeable hardware and/or implant loosening, the presence of the hardware in the appropriate position without cage subsidence and/or implant loosening, and noticeable stable alignment of the spine post-surgery. * Since all products are market-released, assessment for stabilization will be completed by the investigator. * Stabilization will be assessed by the collection of radiographic evidence (X-Ray(s) and CT-scan(s)).

    Time frame: Up to 12 months

  7. Deformity Correction (for specified Medtronic eligible market-released device(s) used from the following product groups: Spinal Tethers)

    Defined by the change of Cobb angle at 12-month

    Time frame: 12 months

Secondary outcomes

  1. Rate of Device-related Adverse Events any Medtronic eligible market-released Cranial & Spinal Technologies (CST) device(s) as aligned with ISO 14155 standards

    The secondary endpoint is defined as the rate of occurrence for device-related adverse events

    Time frame: 24 months

  2. Stabilization [for any Medtronic eligible market-released device(s) used from the following product groups: Interbodies and Biologics, Rods and Screws]

    * Stabilization is the radiographic verification of no noticeable hardware and/or implant loosening, the presence of the hardware in the appropriate position without cage subsidence and/or implant loosening, and noticeable stable alignment of the spine post-surgery. * Since all products are market-released, assessment for stabilization will be completed by the investigator. * Stabilization will be assessed by the collection of radiographic evidence (X-Ray(s) and CT-scan(s)).

    Time frame: Up to 12 months

  3. Deformity Correction [for specified Medtronic eligible market-released device(s) used from the following product groups: Rods and Screws]

    * Deformity correction is defined by the change of Cobb angle at the 12-month postoperative visit compared to baseline. * Assessment(s) for deformity correction will be completed by the investigator. The investigator will determine whether the subject meets requirements of deformity correction based on the comparison of the Cobb angle measurements at all postoperative visits, when compared to the subject's baseline assessments. * Cobb angle measurements will be provided through collection of radiographic evidence (X-Ray(s) and CT-scan(s)) and assessed by the investigator.

    Time frame: 12 months

07

Study locations

28 of 29 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for May 2031, 96 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
May 12, 2023
StartActual
May 1, 2023
Primary completionEst.
May 2031
CompletionEst.
May 2031
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05856370
Responsible party
Sponsor
First posted
May 12, 2023
Start date
May 1, 2023
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Aug 17, 2026

Study contacts

Lauren Oien
Contact
lauren.k.oien@medtronic.com
+17635268124
Erwan Diarra
Contact
erwan.diarra@medtronic.com
+33 7 86 55 72 84

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion